1. Home
  2. ARDX vs WLYB Comparison

ARDX vs WLYB Comparison

Compare ARDX & WLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

N/A

Current Price

$5.69

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Logo John Wiley & Sons Inc.

WLYB

John Wiley & Sons Inc.

N/A

Current Price

$36.58

Market Cap

1.6B

ML Signal

N/A

Company Overview

Basic Information
Metric
ARDX
WLYB
Founded
2007
1807
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Books
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
ARDX
WLYB
Price
$5.69
$36.58
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$15.14
N/A
AVG Volume (30 Days)
3.7M
455.0
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
3.84%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,607,000.00
N/A
Revenue This Year
$38.22
$0.02
Revenue Next Year
$33.85
$2.32
P/E Ratio
N/A
$15.27
Revenue Growth
N/A
N/A
52 Week Low
$3.50
$29.16
52 Week High
$8.40
$45.16

Technical Indicators

Market Signals
Indicator
ARDX
WLYB
Relative Strength Index (RSI) 34.97 67.78
Support Level $5.49 $36.20
Resistance Level $6.23 $38.63
Average True Range (ATR) 0.31 0.53
MACD -0.06 0.82
Stochastic Oscillator 11.79 94.16

Price Performance

Historical Comparison
ARDX
WLYB

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

Share on Social Networks: